Trials / Conditions / Carcinoma of the Head and Neck

Carcinoma of the Head and Neck

9 registered clinical trials studyying Carcinoma of the Head and Neck.

Status	Trial	Sponsor	Phase
Withdrawn	Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357	Travera Inc	—
Completed	Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430	Travera Inc	—
Completed	Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell NCT03733210	Andrei Iagaru	Phase 1
Completed	Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and N NCT02626000	Amgen	Phase 1
Unknown	Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District NCT03001570	European Institute of Oncology	Phase 2
Completed	Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squam NCT00865098	Merck KGaA, Darmstadt, Germany	Phase 2
Withdrawn	Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer NCT00257335	Nilam Ramsinghani	Phase 2
Terminated	Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck NCT00184028	University of Southern California	Phase 2
Completed	Phase II Trial of Allovectin-7® for Head and Neck Cancer NCT00050388	Vical	Phase 3